Æterna Zentaris

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Æterna Zentaris Inc.
Industry Biotechnology
Headquarters Quebec, Canada
Key people
  • Prof. Juergen Engel, Ph.D.
  • Jude Dinges (COO)
Website www.aezsinc.com

Æterna Zentaris Inc. is a Quebec, Canada-based biopharmaceutical drug development company focused in oncology and endocrine therapy,[2] currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. It has over 80 employees in Canada, United States and Germany. The company is based in Canada, the development and research site is based in Germany. The company has 3 lead projects: an ongoing Phase 3 trial in multiple myeloma (a form of blood cancer) conducted under a Special Protocol Assessment (SPA): a Phase 3 trial in endometrial cancer with AEZS-108 expected to be initiated in 1Q 2013, and a New Drug Application (NDA) expected to be filed in 1Q 2013 for the approval of AEZS-130 as potentially the first oral diagnostic test for adult growth hormone deficiency (AGHD).

Perifosine: Fast track designation and orphan drug status granted by the FDA. Orphan Medicinal Product designation and positive Scientific Advice granted by the EMA .

AEZS-108: Orphan drug and Orphan medicinal product designations granted by the FDA and EMA respectively, for the treatment of ovarian cancer.

AEZS-130: Orphan drug designation granted by the FDA for use as a diagnostic test for AGHD.[3]

Corporate governance[edit]

As of December 2013, the company's Chief Commercial Officer is Jude Dinges.[2][4]


  1. ^ "Company Profile for Aeterna Zentaris Inc (CA;AEZ)". Retrieved 2008-10-10. 
  2. ^ a b Slatko, Joshua (December 2013). "BMS changes senior management team". People on the Move: Biopharma. Med Ad News. p. 27. 
  3. ^ "Are things finally looking up for AEterna Zentaris?". 5 Dec 2010. 
  4. ^ "People". Genetic Engineering & Biotechnology News (paper). 33 (21). December 2013. p. 53.